Lupin Ltd. has entered into several strategic agreements to expand its pharmaceutical product offerings globally. On June 16, Lupin signed a license and supply agreement with Sino Universal Pharma to commercialize its Tiotropium dry powder inhaler, used to treat chronic obstructive pulmonary disease, in China. Subsequently, Lupin launched Prucalopride tablets in the United States on June 26 and introduced an Ipratropium Bromide nasal solution on July 4. On July 9, Lupin entered into a license and supply agreement with Zentiva for the global commercialization of its biosimilar Certolizumab Pegol. Under this collaboration, both companies will invest in the development of the biosimilar, with Lupin responsible for development, manufacturing, and initial commercialization. Lupin will receive an initial payment of $10 million upon execution of the agreement and will also obtain total development and supply rights.